Tecartus Granted New Leukemia Indication
October 5, 2021FDA Approves Novel Treatment for Rare Immune Disorder in Children
October 11, 2021October 8, 2021 – TavneosTM (avacopan – ChemoCentryx) is now U.S. FDA approved for use in adults as an adjunct to standard therapy (including glucocorticoids) to treat severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis [granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)].
- ANCA-associated vasculitis is a potentially fatal autoimmune condition. It causes the inflammation and destruction of small blood vessels, leading to organ damage and organ failure.
- Tavneos is the first FDA-approved, orally administered drug in a class known as complement C5a receptor inhibitors.
- Recommended dosing is 30mg (three 10mg capsules) taken by mouth twice daily with food.
- Tavneos has launched at a wholesale acquisition cost (WAC) of $14,450 per one-month supply.